Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis

Recruiting now

Conditions studied: Autoimmune Pancreatitis, IgG4-Related Diseases, Pancreatic Cancer, Chronic Pancreatitis

In brief

This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.

Key facts

Study ID

NCT07536841

Run by

Military Medical Clinical Center of the Southern Region, Ukraine

People needed

82

Starts

2026-05-01

Expected to finish

2026-12-01

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.
• Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring.
• Ability to provide informed consent (for prospective participants).

You may not qualify if…

• Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology).
• Incomplete diagnostic data preventing OC26 scoring.
• Prior pancreatic surgery altering diagnostic interpretation.

Where it is running

• Military Medical Clinical Center of the Southern Region — Odesa, Ukraine (enrolling)
• Military Medical Clinical Center of the Southern Region — Odesa, Ukraine (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.